08:29 AM EST, 11/25/2024 (MT Newswires) -- Eton Pharmaceuticals ( ETON ) said Monday it has acquired US rights to Amglidia oral suspension for neonatal diabetes mellitus from French biotech company AMMTeK.

The drug is approved in Europe and was granted orphan drug designation by the US Food and Drug Administration, Eton said.

Eton said it plans to meet with the FDA in Q1 2025 and aims to submit a new drug application for Amglidia in 2026.